Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
This study identifies HER2 IHC discordance and specific genomic and immune features as prognostic biomarkers of T-DXd efficacy. These findings warrant prospective validation and may inform biomarker-driven strategies to optimize T-DXd therapy in HER2-expressing malignancies.
Authors
- Elias Bou Farhat (ORCID: https://orcid.org/0009-0001-0063-0518)
- Shun‐Fat Lau (ORCID: https://orcid.org/0000-0002-8527-3205)
- Caroline S. Jansen
- Hassan Abushukair (ORCID: https://orcid.org/0000-0002-0068-5201)
- Ann H. Partridge (ORCID: https://orcid.org/0000-0002-4722-4824)
- Sara M Tolaney
- Toni K. Choueiri (ORCID: https://orcid.org/0000-0002-9201-3217)
- Elio Adib (ORCID: https://orcid.org/0000-0003-0594-7976)
- Marc Machaalani (ORCID: https://orcid.org/0000-0002-6708-9922)
- Elizabeth P. Henske (ORCID: https://orcid.org/0000-0001-7978-6699)
- Mehrdad Rakaee (ORCID: https://orcid.org/0000-0002-9080-0153)
- Eric P. Winer (ORCID: https://orcid.org/0000-0002-8819-1723)
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Abdul Rafeh Naqash (ORCID: https://orcid.org/0000-0001-7622-720X)
- David J. Kwiatkowski (ORCID: https://orcid.org/0000-0002-5668-5219)
- S. Salem (ORCID: https://orcid.org/0000-0002-4223-6025)
- Wang Xiao (ORCID: https://orcid.org/0009-0007-1589-6830)
- Kerri Rall
- P. Narendra Babu
- Lill-Tove Rasmussen Busund
- Pavan Challa
- Yamato Takabe
- Michel Alchoueriy
Institutions
- Oslo University Hospital (NO)
- Brigham and Women's Hospital (US)
- University Hospital of North Norway (NO)
- Yale Cancer Center (US)
- Yale University (US)
- Dana-Farber Cancer Institute (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1093/jnci/djaf344
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00